schizandrin has been researched along with Acute Lung Injury in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, L; Huang, Q; Li, W; Liu, Y; Niu, X; Song, H; Yang, Y; Yu, J | 1 |
1 other study(ies) available for schizandrin and Acute Lung Injury
| Article | Year |
|---|---|
Schisandrin improves lipopolysaccharide-induced acute lung injury by inhibiting the inflammatory response in vivo and in vitro.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Cyclooctanes; Lignans; Lipopolysaccharides; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Polycyclic Compounds; Sepsis | 2022 |